Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."
26 November 2014 | Huffington Post
What do women want? While two trials test vaginal rings to fight HIV, market research highlights respondents’ interests in different options.
14 November 2014 | Science Speaks
Most microbicides work by targeting the virus itself, attempting to break it down or blocking its ability to infect a cell. However, the heightened infectiousness of HIV in the presence of semen appears to over-power any anti-viral effects the microbicides possess. The one exception to this finding is a different type of microbicide that acts on the host cells' receptors, stopping the virus from latching on from within. In the current study, this microbicide, [containing the drug called] called Maraviroc, was equally effective in preventing infection both with and without the presence of semen.
13 November 2014 | MedicalXpress
A recent journal article reviewed the challenges and successes in developing rectal microbicides, including the state of the current field, which we summarize here.
11 November 2014 | BETA blog
At this first international meeting to bring researchers from all biomedical HIV prevention approaches together under one roof, neither the time and disappointments leading up to this point, or the uncertainty of how much more time lies ahead, did anything to dampen a sense of optimism and ambition that AVAC director Mitchell Warren sums up as “momentum.”
05 November 2014 | Science Speaks
University of Washington researchers have created a discreet, quick-dissolving tampon out of silk-line fibers to protect women from HIV. The researchers would ideally like to develop a tampon to protect against HIV, herpes, and pregnancy — an all-in-one shield against the risks of sex. This could prove especially useful in developing countries, where women may not have easy access to other kinds of birth control.
04 November 2014 | Healthline News
A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex, whereas just two doses per week can protect men from HIV infection via anal sex. This finding helps explain why two large clinical trials testing HIV pre-exposure prophylaxis, or PrEP, in women failed to show efficacy
31 October 2014 | National Institute of Allergy and Infectious Diseases (NIAID) press release
“People around the world have mysterious notions about the vagina,” Sharon Hillier told a group of journalists and advocates today. Hillier, one of five co-chairs of HIV R4P, the first global conference devoted to biomedical HIV prevention research, is here to explain her work, which she sums up as making vaginas much more resistant to […](Read more...)
28 October 2014 | Science Speaks
Australian biotech company Starpharma has announced the imminent launch of a condom coated with an antimicrobial chemical known as VivaGel. While it might be marketed as a great leap forward for preventing sexually transmitted infections (STIs), it’s unlikely to offer any more protection than your average condom.
14 October 2014 | The Conversation
IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.
02 October 2014 | IRMA